ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO1013

Novel Approaches to Modulate T Cell Responses Based on Insights from Tumor Metabolism: Lactate and Pyruvate Control T Cell Function through NAD Redox Metabolism

Session Information

Category: Transplantation

  • 1701 Transplantation: Basic and Experimental

Authors

  • Beier, Ulf H., Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
  • Jiao, Jing, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
  • Wang, Zhonglin, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Quinn, William J, University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Baur, Joseph A., University of Pennsylvania, Philadelphia, Pennsylvania, United States
  • Hancock, Wayne W., Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
  • Levine, Matthew H., University of Pennsylvania, Philadelphia, Pennsylvania, United States
Background

Solid tumors can evade host immunity due to their distinctive metabolic properties; e.g. the tumor microenvironment can be glucose-depleted but rich in lactic acid, thereby weakening anti-tumor immunity, since cytotoxic and effector T cells require glycolysis to function. We questioned if such insights might suggest novel approaches for T cell suppression in transplant recipients.

Methods

We co-stimulated human and murine CD8+ and CD4+ T cells and exposed them to pH-neutral 5-40 mM sodium L-lactate, D-lactate, or pyruvate, using equimolar NaCl as a control, and measuring T cell proliferation and cytokine production (IL-2, IFN-g, IL-17), and bioenergetics profiles by Seahorse. We measured nicotinamide adenine dinucleotide both in oxidized (NAD+) and reduced (NADH) form, and tested the effects of drugs that oxidize NAD (alpha-ketobutyrate, beta-lapachone, pyrroloquinoline quinone), or impair NAD recycling (FK 866) or NAD oxidation/reduction via lactate dehydrogenase (LDH) inhibition (GSK 2837808A). We induced a tumor-like glycolytic metabolism in MHC-mismatched cardiac allografts by perfusing BALB/c hearts with UW solution containing 1 mM phenformin, 1-2 μM oligomycin, 2 μM nicolsamide, or 2.5 μM UK5099 for 1 hour prior to their engraftment in untreated C57BL/6 recipients.

Results

Sodium L- (& D-) lactate reduced NAD+ to NADH in an LDH(D)-dependent manner, impaired T cell proliferation, and increased induced Foxp3+ Treg formation. Sodium pyruvate achieved the opposite, oxidized NADH to NAD+, reduced iTreg formation, and increased effector T cell proliferation. Bioenergetic measurements showed that in activated effector T cells, NAD+ oxidation increased, while NADH reduction impaired glycolysis, showing that T cell function depends on the NAD:NADH redox status, and less on the absolute amount of NAD. Interestingly, transiently inducing a glycolytic metabolism in MHC-mismatched cardiac allografts prolonged allograft survival for several days.

Conclusion

NAD redox metabolism controls T cell function through aerobic glycolysis, and inducing glycolytic metabolism in cardiac allografts can promote allograft survival. These data provide a rationale for testing further approaches to modulate NAD redox metabolism in allograft recipients.

Funding

  • Other NIH Support